Rigel Pharmaceuticals gets Rezlidhia FDA approval for AML

Raghuram Kadari- December 6, 2022

Rigel Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its Rezlidhia (olutasidenib) capsules for relapsed or refractory (R/R) acute myeloid ... Read More